Presentation AHA 2017 Impact of Regionalization of ST Elevation Myocardial Infarction Care Presenter: James G. Jollis November 14, 2017
Presentation AHA 2017 Time at Blood Pressure Target and the Risk of Cardiovascular Diseases and Mortality Presenter: Mar Pujades-Rodriguez November 14, 2017
Presentation AHA 2017 Subgroup Analysis from the RE-DUAL PCI Trial Presenter: Jonas Oldgren November 14, 2017
Presentation AHA 2017 Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program Presenter: Kenneth W. Mahaffey November 14, 2017
Presentation AHA 2017 Effects of Anacetrapib on the Incidence of New-Onset Diabetes Mellitus and on Vascular Events in People With Diabetes Presenter: Louise Bowman November 14, 2017
Presentation AHA 2017 Prevention of Serious Adverse Events Following Angiography (PRESERVE) Trial Presenter: Steven Weisbord November 13, 2017
Presentation AHA 2017 Clinical Benefit of Minimally-Interrupted Dabigatran versus Uninterrupted Warfarin for Catheter Ablation of Atrial Fibrillation: A Prospective Randomized Multicenter Trial Presenter: Akihiko Nogami November 13, 2017
Presentation AHA 2017 One-Year Outcomes: Prasugrel vs Ticagrelor in AMI Treated With PPCI PRAGUE-18 Study Presenter: Zuzana Motovska November 11, 2017
Presentation AHA 2016 Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart Failure (EFFECT-HF) Presenter: Dirk J. van Veldhuisen November 16, 2016
Presentation AHA 2016 Transcatheter Intracardiac Shunt Device Provides Sustained Clinical Benefit at One Year in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: The REDUCE LAP Heart Failure Trial Presenter: David M Kaye November 15, 2016
Presentation AHA 2016 PIONEER Trial: An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy Presenter: Michael Gibson November 15, 2016
Presentation AHA 2016 Arterial Revascularization Trial (ART) Presenter: David P. Taggart November 15, 2016
Presentation AHA 2016 The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Human ApoA-I, After Acute Myocardial Infarction: The ApoA-I Event reducingG in Ischemic Syndromes I Trial (AEGIS-I) Presenter: Michael Gibson November 15, 2016
Presentation AHA 2016 GLAGOV Trial: Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound Presenter: Steven E. Nissen November 15, 2016
Presentation AHA 2016 FUnctional Testing Underlying REvascularization: The FUTURE trial Presenter: Gilles Rioufol November 15, 2016
Presentation AHA 2014 Primary Outcomes of the EVOLVE II Trial: A Prospective Randomized Investigation of a Novel Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent Presenter: Dean J. Kereiakes November 16, 2014
Presentation AHA 2014 Long-term Outcome of Biodegradable Compared to Durable Polymer Drug-Eluting Stents and Bare Metal Stents – Main Results of a Prospective Randomized Trial Presenter: C.Kaiser November 16, 2014
Presentation AHA 2014 Efficacy and safety of vorapaxar in NSTE ACS patients undergoing non-cardiac surgery Presenter: S. van Diepen November 16, 2014
Presentation AHA 2012 Endovascular Treatment for Infrainguinal Vessels in Patients with Critical Limb Ischemia: OLIVE Registry, a Prospective, Multicenter Study in Japan with 12-month Follow-up Presenter: Masato Nakamura November 06, 2012